01.11.2010 | Consensus report | Ausgabe 21-22/2010

Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: Results of an Austrian gynecologic oncologists' expert meeting
- Zeitschrift:
- Wiener klinische Wochenschrift > Ausgabe 21-22/2010